Description
Therapies that target the PD-1 receptor have shown unprecedented results with high levels of clinical response in patients with various cancer types (3). The presence of PD-1 positive tumor-infiltrating lymphocytes (TIL) has been associated with poor prognosis in human breast cancers and may be useful in antibody therapy targeting the PD-1/PD-L1 signaling pathway (1). Treatments targeting PD-1 and its ligand, PD-L1, have also shown encouraging results in non-small-cell lung cancer, renal cell carcinoma and melanoma (4-6).
Specifications
| INTENDED USE | RUO |
|---|---|
| FORMAT | Concentrate, Predilute, VALENT |
| VOLUME | 0.1 ml, 1.0 ml, 20 ml, 6.0 ml |
| SOURCE | Mouse Monoclonal |
| CLONE | NAT105 |
| ISOTYPE | IgG1/kappa |
| ANTIGEN | PD-1 |
| LOCALIZATION | Cytoplasmic |
| POSITIVE CONTROL | Tonsil |
